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Life-threatening group B streptococcal infections in neonates have become a major 
problem throughout the United States and many other parts of the world (1).  It has 
been estimated that within the United States, -~ 15,000  babies each year develop sepsis 
or meningitis due to this organism, with a  high rate of morbidity and mortality (1). 
Why  this  disease  has emerged as an  increasing problem over the  last  10  yr is  not 
known.  Recent studies have suggested that a  deficiency of type-specific antibody in 
newborn  infants  may be an  important  factor in  predisposing  them  to  developing 
group B streptococcal disease (2). 
Immunity to Streptococcus pneumoniae and Streptococcus agalactiae (group B streptococ- 
cus)  is  primarily related  to  their  capsular  polysaccharide  antigens  (3,  4).  Opsono- 
phagocytic studies  have demonstrated  type specificity of opsonic antibody directed 
against  each  of the  five types of group  B  streptococci,  although  occasional  cross- 
reactions have been detected  (3). 
Using  immunoelectrophoresis,  we  recently  demonstrated  that  antisera  directed 
against S. pneumoniae type 14 reacts with the hot HCl-extracted polysaccharide antigen 
of group B streptococci type III (5).  The present studies were designed to determine 
if antisera directed against S. pneumoniae type 14 are opsonic for group B streptococci 
type III in  a  neutrophile  bactericidal  assay and  afford protection  in  a  suckling  rat 
model of neonatal group B streptococcal type III sepsis. 
Materials and Methods 
Streptococcal Strains.  Group B streptococcal strain, IIINor, isolated  from the cerebrospinal 
fluid  of an infant with meningitis was used  in most of these studies.  Precipitin and opsonic 
analysis confirmed IIINor to be a type III strain. For neutrophiles to demonstrate bactericidal 
activity against IIINor, both type-specific antibody and complement were required. Group B 
streptococci  type III, strain SS620, and group B streptococci  090R,  a strain devoid of type- 
specific antigen (6), were kindly supplied by Dr. Hazel Wilkinson,  Center for Disease Control, 
Atlanta, Ga. S. pneumoniae type 14 strain SP14 and type 3 strain SP42 were kindly supplied by 
Dr.  Byrd Smith, also of the Center for Disease Control. Organisms were grown to mid log 
phase in Todd-Hewitt broth, and stored at -70°C until used. 
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Preparation of Antisera.  Adult New  Zealand white rabbits weighing ~-3  kg were  injected 
intravenously with formalin-killed group B streptococci type III, S. pneumoniae type  14, or S. 
pneumoniae type 3, according to the general protocol of Wilkinson and Moody (7). Sera from all 
animals were evaluated before immunization to insure the absence of opsonic antibody to the 
study organisms. The organisms were cultured overnight at 37°C in 200 ml of Todd-Hewitt 
broth. The cells were sedimented by centrifugation, washed, and resuspended in 0.2% formalin 
in phosphate-buffered saline for 5-7  days at  4°C.  Cultures were  performed daily to assess 
sterility. After dilution to restore the original concentration, 1.0 ml of the nonviable bacterial 
suspension was given daily for 5 days followed  by a  1-wk rest.  This series of injections were 
repeated  three  times.  After  a  l-mo rest,  the  animals were  given two  additional series  of 
injections. 
The animals were bled via cardiac puncture 4-5 days after the third and fifth series  of 
injections. Serum was removed from the clotted blood, heat-inactivated at 56°C for 30 min, 
and stored in 0.5-ml aliquots at -70°C. 
Neutrophile Opsonophagocytic Bactericidal Assay.  Neutrophiles were isolated from normal adult 
volunteers by dextran sedimentation followed  by FicolI-Hypaque density centrifugation (8). 
The cell population used consisted of >98% viable neutrophiles. These cells were washed once 
in normal saline and then resuspended at a concentration  of 25 ×  l0  s eells/ml. The bactericidal 
capability of neutrophiles was tested in a modified form of the assay of Hirseh and Strauss (9). 
Use of a microtiter plate technique to measure neutrophile-mediated bactericidal activity was 
developed by Dr. J. C. Sadoff. 1 The microtiter plate technique (modified so that bacteria could 
be adequately dispersed by vigorous vortex and/or sonication) described by Cross and Lowell 2 
was used in this study with only minor modification. The technique requires a total volume of 
0.1 cc/well and allows efficient testing of numerous variables using small amounts of sera and 
neutrophiles. For the assay, bacteria were taken during mid log phase growth in Todd-Hewitt 
broth,  washed  once, and then appropriately diluted in Eagle's medium.  10 #1  (containing 
0.4-4.0  ×  106  bacteria)  were  added  to  round-bottom microtiter wells  along with 40 #1  of 
neutrophiles (containing  0.5-2.0 ×  106 neutrophiles), 10 pl of newborn rabbit serum (screened 
for absence of antibody activity against test organisms) as a source of active complement, and 
40 #1 of various dilutions of heat-inactivated pre- or post-immunization  rabbit serum. Control 
wells in every experiment consisted of (a)  neutrophiles alone, (b) complement alone, and (c) 
neutrophiles plus complement. In addition, serum with known opsonic activity and serum 
known  to  lack  opsonic  activity were  included as  positive  and  negative controls  in  each 
experiment. The microtiter plates were then sealed with pre-cut acetate sealing tape (Cooke 
Laboratory Products,  Div.  Dynateeh Laboratories Inc., Alexandria, Va.)  and incubated at 
37°C with constant vigorous shaking. 
To determine neutrophile bactericidal activity, 10-#1 samples were taken from each well at 
zero time and also after 1 and 2 h of incubation. Before plating the bacteria onto blood agar, 
the samples were appropriately diluted in test tubes containing  0.1% bovine serum albumen in 
distilled water; the samples were then vigorously vortexed. This ensured that neutrophiles were 
selectively lysed and that bacteria were adequately dispersed. 
Neutrophile  bactericidal  activity was  calculated  by  the  formula  100-(100) (number of 
bacteria at 60 or 120 min)/(number  of bacteria in the initial inoculum); 0% represents bacterial 
growth. 
Absorption of Antisera.  Sera collected after five series of injections were absorbed. Adsorbing 
bacteria were grown overnight on blood agar~ scraped from the plate, suspended in normal 
saline, and then pelleted in 0.5-ml mierofuge tubes to one-fifth the volume of the tube. After 
adding 0.4 ml of serum, the tubes were vortexed and then rotated at slow speed on an end-over- 
end  tumbler  (Fisher  Rotorack  model  343,  Fisher  Scientific Co.  Pittsburgh,  Pa.)  at  4°C 
overnight.  The  following day  the  bacteria were  sedimented in a  microfuge tube and  the 
supernatant sera were removed and filtered through a 0.2-#m membrane filter. The sterile sera 
were then used either directly or after storage at -70°C. 
Neonatal Sepsis  Model  Pregnant Wistar rats  were  obtained from  a  commercial breeder 
1  j. C. Sadoff. Manuscript in preparation. 
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(Charles  River Breeding  Laboratories,  Wilmington,  Mass.),  housed  on  polycarbonate cages 
with hardwood litter, and given antibiotic free food and water ad libitum. 
Bacteria inocula frozen in Todd-Hewitt broth were thawed and subcultured on blood agar 
plates  the  day  before  animal  injection.  Bacteria  scraped  from  the  blood  agar  plate  were 
suspended in Todd-Hewitt broth to the desired optical density (0.03 at 650 nm using a Coleman 
spectrophotometer from Coleman Systems, Irvine, Calif.) and placed in a shaker bath at 37°C 
for -~2½ h. When the desired optical density (0.6) was achieved, the organisms were sedimented 
by centrifugation, washed once, and then resuspended in Todd-Hewitt broth to a concentration 
of ~-107 colony-forming units/ml. 
Suckling rats (2-3 days old) were injected subcutaneously with 0.02 mi (=-l0  s viable bacteria) 
of the group B streptococcal suspension  administered just  cephalad  to the tail.  Immediately 
after inoculation,  the study animals were given an intraperitoneal  injection  (0.1 or 0.2  ml of 
antisera) directed against group B streptococci type III or S. pneumoniae types 3 or 14. Controls 
consisted of untreated  littermates.  All  animals were observed daily for the study period of 5 
days to determine survival. In this model, deaths are rarely encountered  later than 72 h after 
infection. 
Antisera  used  in  these  studies  were of relatively  low  titer  (obtained  after  three  series of 
injections) except in one litter (no.  53) in which high titer antiserum (obtained after five series 
of injections) was utilized. 
Results 
Opsonophagocytic Bactericidal Studies 
HOMOLOGOUS ANTISERA.  The ability of neutrophiles to phagocytize and kill group 
B streptococci type III (IIINor) and S. pneumoniae type  14 was studied  in the presence 
of antisera directed against  these organisms.  After  1 and 2 h  of incubation,  >90%  of 
the  initial  inoculum  were  killed  (Figs.  1 and  2).  In  the  absence  of serum,  or  in  the 
presence of sera obtained before immunization,  neutrophiles did not impede bacterial 
growth  (Figs.  1 and 2). 
HETEROLOGOUS ANTISERA.  Antisera were analyzed for activity against heterologous 
organisms. Antisera directed against S. pneumoniae type 14 enabled neutrophiles  to kill 
>90% of an inoculum of group B streptococci type III (Fig.  1). Significant  killing by 
neutrophiles  was also accomplished  when  S. pneumoniae type  14 were opsonized  with 
type III group B streptococcal antisera  (Fig.  2). 
EFFECT OF DILUTION OF SERUM ON OPSONOPHAGOCYTIC BACTERICIDAL ACTIVITY.  The 
data in Table I are based on sera obtained after three series of injections and describe 
their  activity  against  group  B  streptococci  type III. These sera are of relatively low 
titer.  At  a  dilution  of  1:10  ,  anti-group  B  streptococcal  type  III  serum  enabled 
neutrophiles  to kill >85% of the initial  inoculum  after both  1 and 2 h  of incubation. 
When sera directed against S. pneumoniae type 14 were used, comparable neutrophile- 
mediated  bactericidal  activity was observed at  a  serum  dilution  of 1:5.  In contrast, 
antisera  directed  against  S. pneumoniae type 3  did  not  opsonize  group  B  streptococci 
type III to allow significant  neutrophile  killing. 
Since three series of injections  resulted  in relatively low titers of opsonophagocytic 
bactericidal  activity,  rabbits  were  immunized  with  two  further  series  of injections. 
Sera  obtained  from  these  animals  demonstrated  significantly  higher  titers  (Fig.  3). 
These  data  represent  the  averaged  results  of  six  separate  experiments.  Antisera 
induced by S. pneumoniae type 14 were virtually as effective as the homologous antisera 
in  facilitating  the  killing  of group  B  streptococci  type  III, e.g.  >90%  kill  after  2  h 
incubation  at  1:80 dilution. G.  FISCHER,  G.  LOWELL,  M.  CRUMRINE, AND J.  BASS 
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Fro.  1.  Effect  of rabbit  antisera on group B streptococci type III in a neutrophile bactericidal 
assay. Conditions for the assay were as follows:  no serum given; serum obtained before immunization 
(preimmune); antisera directed against group B streptococci type III (GBS III); antisera directed 
against S. pneurnoniae  type 14 (PI4). 
Studies similar to those using group B streptococci type III were performed using 
S. pneumoniae type 14 as the test organism  (Fig.  4).  Review of the data presented in 
Figs. 3 and 4 shows that the heterologous activity of anti-S, pneumoniae type  14 serum 
against group B streptococci type III is comparable to the activity against S. pneumoniae 
type 14 itself. Interestingly, antisera directed against group B streptococci type III did 
not show the same degree of cross-reactivity. 
ANTIGENIC SPECIFICITY  OF RABBIT  ANTISERA.  Absorption studies were performed to 
determine  the  specificity  of the  opsonic  reaction  to  group  B  streptococci  type  III 
(Table II). When antisera directed against S. pneumoniae type 14 was adsorbed with S. 
pneumoniae  type  14  or  group  B  streptococci  type  III organisms  (IIINor or  SS620), 
opsonophagocytic  bactericidal  activity  against  group  B  streptococci  type  III  was 
abolished.  In  contrast,  after  absorption  with  group  B  streptococci  090R  (a  strain 
devoid  of type-specific  antigen),  or with  S.  pneumoniae  type  3,  bactericidal  activity 780  OPSONIZATION OF GROUP B TYPE  III STREPTOCOCCI 
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FIG. 2.  Effect of rabbit  antisera on S. pneumoniae type  14 in  a  neutrophile  bactericidal assay. 
Conditions for the assay were: no serum given; serum obtained before immunization (preimmune); 
antisera  directed against group  B streptococci type III (GBS III); antisera  directed against  S. 
pneumoniae type 14 (P14). 
persisted.  S. pneumoniae  type  14  was  as effective as  group  B  streptococci  type III in 
absorbing opsonic activity from serum directed against group B streptococci type III 
(Table II). 
Protection  Studies.  Administration  of rabbit  antisera  directed  against  the homolo- 
gous  group  B  streptococci  type  III  (IIINor)  and  administration  of heterologous 
antisera against S. pneumoniae type 14 both resulted in significant survival in this model 
of group B streptococcal sepsis  (Fig. 5). Neonatal rats given rabbit S. pneumoniae type 
3  antisera  and  those  animals  not  given  antisera  did  not  survive.  55  of 59  control 
animals  (this includes animals given S. pneumoniae type 3 antisera as a  serum control 
and those animals not treated with antisera)  were dead within 48 h  of infection and 
all  control  animals  had  died  by  72  h.  In contrast,  20 of 22  animals  given  antisera 
directed  against  group  B  streptococci  type  III  and  17  of  18  animals  given  anti- 
pneumococcal type  14 antisera were still  alive at the end of the 5-day study period. G.  FISCHER,  G.  LOWELL,  M.  CRUMRINE,  AND J.  BASS  781 
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No. of viable bacteria/ml  ×  10  -6 
PMN bactericidal ac- 
tivity* 
0 min  60 min  120 min  60 min  120 min 
None 
Preimmune 
0  8.6  17.2  30.4  0  0 
1/2.5  6.2  17.2  27.6  0  0 
1/5  7.0  14.0  22.0  0  0 
1/I0  6.4  16.8  28.0  0  0 
1/20  6.0  16.4  22.8  0  0 
1/40  6.5  13.2  24.4  0  0 
Anti-GBS III  1/2.5  7.3  0.3  0.1  96  99 
1/5  9.6  1.7  0.2  82  98 
1/10:~  19.2  1.2  0.8  94  96 
1/20§  14.0  3.7  6.0  74  57 
1/40  24.0  16.4  9.2  32  61 
1/80  11.2  6.5  30.8  0  0 
Anti-Pl4  1/2.5  9.8  1.2  1.5  99  85 
1/5:[:  14.8  1.9  0.8  87  95 
1/10  11.7  6.2  6.9  47  41 
1/20§  15.6  7.1  4.9  54  69 
1/40  8.0  6.7  8.6  16  0 
1/80  6.8  8.9  10.4  0  0 
Anti-P3  1/2.5  7.0  3.2  64.0  55  0 
1/5  18.8  16.0  77.2  11  0 
1/10  14.4  9.2  85.6  36  0 
1/20  13.2  78.8  80.0  0  0 
1/40  11.6  30.8  80.0  0  0 
GBS  III,  group  B  streptococci  type  III;  P14,  S. pnaononiae type  14;  P3,  S. pneumoniae type  3;  PMN, 
polymorphonuclear neutrophiles. 
* Percent bacteria killed compared to number of viable bacteria present in the initial inoculum (0 rain) 
according to the formula shown in Materials and Methods. 
Highest titer at which >80% of bacteria killed after both 60 and 120 rain of test incubation. 
§ Highest titer at which >50% of bacteria killed after both 60 and 120 min of test incubation. 
Discussion 
Over the last several years, group B streptococcal infections have become increas- 
ingly recognized as a major cause of neonatal infection (8-18): In some areas, group 
B  streptococci  comprise  the  single  most  common  cause  of bacterial  sepsis  and 
meningitis in newborns  (19-21).  Recently, the absence of type-specific antibody in 
maternal and cord sera has been shown to be a major determinant for the development 
of invasive neonatal group B streptococcal disease (2). The observation with immu- 
noelectrophoresis  that  the  hot  HCl-extracted  polysaccharide  antigen  of group  B 
streptococci type III reacted with antisera directed against S. pneumoniae type 14  (5) 
suggested that a common antigen was present in both organisms. The present studies 
demonstrate that antisera directed against S. pneumoniae type 14 not only facilitates 
opsonophagocytic bactericidal activity but also protects suckling rats against death 
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Fro.  3.  The effect of high-titer rabbit antisera on neutrophile bactericidal activity against group 
B  streptococci type III.  Antisera directed against  group  B  streptococci type III  (GBS  III)  were 
incubated for  120 min  (e) and 60 min  (©). Antisera directed against S. pneumoniae type  14  (PI4) 
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Fro.  4.  The  effect of high-titer rabbit  antisera  on  neutrophile  bactericidal  activity  against  S. 
pntumoniae type 14. Antisera directed against group B streptococci type III (GBS III) were incubated 
for 120 min (0) and 60 min (O). Antisera directed against S. pnaononiat  type 14 (PI4) were incubated 
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TABLE  II 
The Effects of Adsorption  with Homologous or Heterologous Bacteria on the Ability of Rabbit Antisera to 
Opsonize GBS III 
Antiserum  Adsorbing bacteria 
No. of viable  PMN bacteri- 
bacteria/ml  X  10  -~  cidal activity 
against GBS 
III at  120 
0 min  120 rain 
min* 
Pl4~ 
GBS III§ (Nor) 
% 
None  4.3  0.2  95 
PI4  6.6  >8.0  0 
GBS III (Nor)  10.4  28.0  0 
GBS III (620)  5.0  >8.0  0 
GBS 090R  5.6  0.7  87 
P3  18.0  0.4  98 
None  7.5  0.04  99 
GBS llI (Nor)  5.8  >8.0  0 
PI4  31.2  54.8  0 
GBS III, group B streptococci type III; GBS 09OR, group B streptococci strain 09OR;  P14, S. pneumoniae 
type 14; P3, S. pneumoniae type 3; PMN, polymorphonuclear neutrophiles. 
* Percent bacteria killed compared to number of viable bacteria in the initial inoculum (0 min) according 
to the formula shown in Materials and Methods. 
~: Serum titers used  =  1/20. 
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FIG. 5.  Effect of type-specific antisera on the survival of suckling rats with experimental type III 
group B streptococcal sepsis. Antisera were directed against S. pneumoniae type 14 (PI4)  (©); group 
B streptococci type III  (GBS  III)  (O);  S. pneumoniae type 3  (P3)  (A); and no serum given  (None) 
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Absorption studies with both S. pneumoniae type 14 and group B streptococci type 
III  demonstrated  that  the  opsonic  antibody  in  both  antisera  is  directed  against 
common antigenic determinants. The fact that group B streptococci type III, strain 
SS620  also  absorbs  out  the  bactericidal  activity  of  antisera  directed  against  S. 
pneumoniae type  14  further suggests that  the common antigenic determinant is  not 
strain-specific for the group B streptococci type III, IIINor, clinical isolate. The 090R 
group B streptococci (devoid of type-specific antigen) and the S. pneumoniae type 3 did 
not remove the opsonic activity. This indicates that the cross-reacting antigen is type- 
specific. These data are consistent with the earlier findings of cross-reactivity between 
the antibody directed against S. pneumoniae type 14 and and the hot HCl-extracted 
polysaccharide capsular antigen of group B streptococci type III (5). 
The chemical composition of the capsular polysaccharide antigens of many types 
of pneumococei have been studied (4). The S. pneumoniae type  14 capsule has been 
shown to contain the amino sugar glucosamine and the neutral sugars galactose and 
glucose, and its structure has been elucidated (4, 22).  Russell and Norcross (23) and 
Baker et al. (24) have reported that the type-specific polysaccharide antigen of group 
B streptococci  type III also contains glucosamine, galactose, and glucose. The im- 
munochemical basis for the cross-reaction we have described may be related to this 
similarity in capsular composition. Strains of other bacterial species cross-reacting 
with S.  pneumoniae type  14  have also been  reported  (25).  Numerous cross-reactions 
between pneumocoeci (non-type 14) and various streptococci (non-group B) have also 
been shown (26). The biochemistry of these cross-reactions, however, is not clear. 
Protection  studies  using  a  suckling  rat  model  of  neonatal  type  III  group  B 
streptococcal sepsis demonstrated that antisera directed against S. pneumoniae type 14 
is highly protective. Group B streptococci type III antisera provided similar protection 
in this model. Since antisera directed against S. pneumoniae type 3 were not effective, 
it seems unlikely that protection is related to a nonspecific serum factor. This inability 
of antisera directed against S. pneumoniae type 3 to afford in vivo protection is further 
evidence that the antigen against which protective antibodies are directed is closely 
associated with the capsular polysaccharide of type 14 pneumococci. 
The protection studies reported in this paper were performed with rabbit antisera 
of relatively low titer collected after three series of injections. Preliminary data from 
our laboratories suggest that the anti-group B type III streptococcal opsonophagocytic 
bactericidal activity of the sera of most  adults  is of similarly low titer. Therefore, 
antibody in maternal serum directed against S. pneumoniae type  14  may be able to 
provide protection against group B streptococci type III in the newborn child. 
With this information, one might speculate that naturally acquired immunity to 
group  B  streptococci  type  III  may  be  related  to  the  development  of antibodies 
secondary to childhood pneumococcal infections. Interestingly, S. pneumoniae type 14 
is one of the most common causes of pneumoeoccal infections in childhood (27). Since 
currently available  pneumococcal  vaccines have been  shown  to  induce antibodies 
directed  against  S.  pneumoniae type  14  (28),  protection  against  neonatal  group  B 
streptococci type III disease may be possible by maternal immunization using these 
vaccines. 
Summary 
The present studies demonstrate that antisera directed against Streptococcus pneumo- 
niae type  14 is opsonic for group B streptococci type III in a  neutrophile-mediated G.  FISCHER,  G.  LOWELL,  M.  CRUMRINE, AND J.  BASS  785 
bactericidal  assay.  Specificity was  demonstrated  by the  observations  that  group  B 
streptococci type III and S. pneumoniae type 14 adsorbed the opsonic activity of anti-S. 
pneumoniae type 14 antisera. Group B streptococci strain 090R (devoid of type antigens) 
and S. pneumoniae type 3, did not remove the opsonic activity of anti-S, pneumoniae type 
14 serum. In vivo studies using a suckling rat model of neonatal group B streptococcal 
type III sepsis demonstrated  that  antisera  directed against S. pneumoniae  type  14 was 
highly protective. 
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